AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03866382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib S-malate
Description: Given PO
Study NCT03866382 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT and/or PET/CT scan
Study NCT03866382 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo echocardiography
Study NCT00464061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Volinanserin
Description: oral administration
Study NCT00464061 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral administration
Study NCT03866382 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV
Study NCT03866382 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT03866382 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT03866382 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT scan
Study NCT02994472 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Gastric emptying scintigraphy using 99mTc-DTPA
Study NCT01217879 — intervention group
Intervention type: DRUG
Intervention: Telmisartan (Kinzal/Pritor, BAY68-9291)
Description: Patients treated with telmisartan tablets under the real-life setting. Dosing regimen customised to the needs of each participating patient according to the investigators assessment
Study NCT03888040 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The participant will attend 3 training sessions per week for 8 weeks. Resistance training will be performed by each leg with a load of 30% of maximal strength: one leg with and the other without blood flow restriction.
Study NCT04717648 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Biochemical test
Description: C Reactive protein and sodium
Study NCT03982719 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brief protocol
Description: This protocol consists of 4 intervention sessions with an occupational therapist specialized in hand therapy that will occur at 0-3 days, 2 weeks, 4 weeks and 8 weeks post-fasciectomy. The occupational therapist will give recommendations about the management of swelling, wound care and functional recovery. An home exercises program will be given to the participant. The occupational therapist will make an extension splint that should be worn at night for the 3 months following surgery.
Study NCT03982719 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intense protocol
Description: This protocol consists of 6 intervention sessions with an occupational therapist specialized in hand therapy that will occur at 0-3 days, 2 weeks, 3 weeks, 4 weeks, 6 weeks and 8 weeks after surgery. The occupational therapist will give recommendations about the management of swelling, wound care and functional recovery. An home exercises program will be given to the participant. The occupational therapist will make an extension splint that should be worn at night for the 3 months following surgery. Also, exercises will be performed by the patient under the supervision of the occupational therapist (supervised exercises) in each session except the first one at 0-3 days after surgery.
Study NCT01267110 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MI2 intervention arm
Description: For persons who are randomized to the MI2 intervention arm, the HLK-BH program will guide participants through a series of questions to fully delineate step-by-step breast cancer screening intentions of participants the when, where and how of screening)and encourage follow through on these intentions.
Study NCT01267110 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Each participant in the C intervention arm will receive the same brief one-on-one breast cancer screening education information delivered in person by a CHW as MI2 participants. In additional participants will go through the Healthy Living Kansas-Breast Health computerized screening and intervention program.
Study NCT02131103 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous coronary intervention
Description: All patients received fibrinolysis, aspirin 300 mg and clopidogrel (300 mg for participants 75 years of age or younger or 75 mg for participants older than 75 years of age). Patients older than 75 years of age did not receive enoxaparin.~Patients will be randomly assigned to either the group that received routine early PCI (hereinafter termed the early-PCI group) or the group that received standard treatment (PCI performed after 24-72 hours of successfully fibrinolysis). Randomized will perform within 24 hours after successful fibrinolytic therapy. PCI will be performed when persistent occlusion or substantial stenosis of the infarct-related artery (either stenosis of 70% or more of the diameter of the artery or stenosis of 50-70% with thrombus, ulceration, or spontaneous dissection) was present. In case of multivessel disease, only culprit lesion will be correct.
Study NCT02042586 — intervention group
Intervention type: OTHER
Intervention: Analysis of movement before total hip replacement
Study NCT02042586 — intervention group
Intervention type: OTHER
Intervention: Analysis of movement after total hip replacement
Study NCT00160017 — intervention group
Intervention type: BEHAVIORAL
Intervention: Breakthrough collaborative
Description: Participants (professionals) participate in a Breakthrough Collaborative to improve diabetes care
Study NCT03619096 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: tunnel technique for Root coverage with Porcine collagen Matrix
Description: Tunnel technique for root coverage for multiple gingival recessions, using porcine collagen matrix
Study NCT03619096 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: extended fla technique for Root coverage with Porcine collagen Matrix
Description: Extended flap technique for root coverage for multiple gingival recessions, using porcine collagen matrix
Study NCT03655301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib (Aliqopa, BAY80-6946)
Description: The copanlisib dose for this study is the standard dose recently approved and also used in Phase 1, 2 and 3 studies across the copanlisib development program: 60 mg i.v. infusion administered intermittently on Days 1, 8 and 15 of a 28-day cycle.~In this study subjects will receive a single i.v. dose of 60 mg copanlisib on day 8.
Study NCT03655301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Single dose of 1000 mg is administered orally.
Study NCT02056886 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: SLN detection +/- complementary axillary lymphadenectomy
Description: breast cancer surgery with SLN detection +/- complementary axillary lymphadenectomy Whatever the detection method used in the lab (Arm A: OSNA; Arm B: Pathological Examination; Arm C: Extemporaneous) to assess the positivity of sentinel lymph-node invasion, if negative result (no tumor invasion in the sentinel LN), a complementary lymph-node dissection is not mandatory if positive result (tumor invasion in the sentinel LN), a complementary lymph-node dissection is performed, either immediately (Arm A and C) or in a second surgical procedure (Arm B)
Study NCT02056886 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SLN detection +/- complementary axillary lymphadenectomy
Description: breast cancer surgery with SLN detection +/- complementary axillary lymphadenectomy Whatever the detection method used in the lab (Arm A: OSNA; Arm B: Pathological Examination; Arm C: Extemporaneous) to assess the positivity of sentinel lymph-node invasion, if negative result (no tumor invasion in the sentinel LN), a complementary lymph-node dissection is not mandatory if positive result (tumor invasion in the sentinel LN), a complementary lymph-node dissection is performed, either immediately (Arm A and C) or in a second surgical procedure (Arm B)
Study NCT01226641 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telemedicine
Description: CPAP treatment with telemedicine system
Study NCT01226641 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Standard care, including CPAP
Study NCT03393819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DuraPrep
Description: DuraPrep surgical solution
Study NCT03393819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ChloraPrep
Description: ChloraPrep surgical solution
Study NCT04147377 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: behavioral intervention based on sensory cues
Description: Patients will receive behavior intervention training that includes how to apply visual and auditory cues to freezing of gait in real clinical practice.
Study NCT03136146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Given SC
Study NCT03136146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: Given IV
Study NCT03136146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT03136146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given IV or PO
Study NCT03136146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV
Study NCT03136146 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: Given IV
Study NCT03136146 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Given SC
Study NCT03136146 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study NCT03136146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate Liposome
Description: Given IV
Study NCT04452071 — intervention group
Intervention type: RADIATION
Intervention: periapical xray
Description: periapical xray on the middle phalanax of the middle finger
Study NCT01212679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nerve growth factor
Description: The experimental group patients will receive NGF 20ug/d intranasally for 2 weeks.
Study NCT01212679 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: nomral saline
Description: The Placebo Comparator group patients will receive nomral saline 20ug/d intranasally for 2 weeks.
Study NCT04699032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apraglutide
Description: Single dose of apraglutide 5 mg.
Study NCT03383913 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Heart Rate Variability Biofeedback
Description: Over a period of 4-6 weeks participants in the intervention arm will learn a series of breathing techniques to determine Heart Rate Variability's effects on physical function, anxiety, depression, fatigue, sleep disturbance, participation in social activities, pain interference and intensity.
Study NCT02402127 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Somofilcon A contact lenses
Description: Silicone hydrogel contact lenses for daily disposable wear
Study NCT02823028 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NRT
Description: 8-weeks of study provided NRT patch, and 8-weeks of study provided NRT gum of varying strengths or 8-weeks of study provided NRT lozenges, depending on patient level of nicotine dependence.
Study NCT02823028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRT
Description: 8-weeks of study provided NRT patch, and 8-weeks of study provided NRT gum of varying strengths or 8-weeks of study provided NRT lozenges, depending on patient level of nicotine dependence.
Study NCT02744118 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 5A's Model
Description: The adapted 5A's model will include the following elements:~1. Ask the patient about their marijuana use~2. Advise every patient to quit/reduce marijuana use using clear, specific personalized advice~3. Assess factors affecting choice of behavior and behavior change~4. Assist abstinence/reduction in in marijuana use using behavior change techniques to aid the patient~5. Arrange follow-up for ongoing assistance and support, and to adjust treatment plans
Study NCT02744118 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Internet Use Model
Description: The Healthy Internet Use Model provides a framework for conversations between pediatric practitioners and their adolescent patients. It focuses on 3 key areas of social media behavior:~1. Balance~2. Boundaries~3. Communication
Study NCT02591186 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Participants will receive 3 acupuncture sessions during IVF process
Study NCT02391129 — intervention group
Intervention type: PROCEDURE
Intervention: Operation for Periprosthetic fractures of the hip with stem loosening
Study NCT00620399 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: lumbar corset
Study NCT00620399 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: lumbar corset
Study NCT02589652 — intervention group
Intervention type: DRUG
Intervention: Pegylated interferon alfa-2a
Description: ETV 0.5mg oral daily plus PegIFN alfa-2a 180ug subcutaneous injection weekly for 8 weeks and followed by PegIFN alfa-2a 180ug subcutaneous injection weekly for 40 weeks
Study NCT02589652 — intervention group
Intervention type: DRUG
Intervention: Pegylated interferon alfa-2a plus Entecavir
Description: ETV 0.5mg oral daily plus PegIFN alfa-2a 180ug subcutaneous injection weekly for 48 weeks
Study NCT02589652 — intervention group
Intervention type: DRUG
Intervention: Entecavir
Description: ETV 0.5mg oral daily for 48 weeks
Study NCT03066700 — intervention group
Intervention type: DEVICE
Intervention: Hemostatic powder
Description: HemosprayTM (Tc-325) is an endoscopic hemostatis powder that came onto market recently. It is made of an inorganic, non-absorbable powder which acts locally at the mucosa. When spraying the powder on to the bleeding site, it creates an adherent stable barrier sheath that allows for at least temporary hemostasis. Neither luminal nor systemic side effects have been reported to date.
Study NCT03365258 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Trophic feeding
Description: Non-blind to randomize to trophic feeding group and volume based feeding group in the first six days (Day 0->Day 6). The definition of trophic feeding is continue feeding with feeding rate: 20 kcal/hr.
Study NCT03365258 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: volume-based feeding
Description: Non-blind to randomize to trophic feeding group and volume based feeding group in the first six days (Day 0->Day 6). The definition Volume-based feeding also use continue feeding by feeding protocol
Study NCT03269968 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy (PREVENA Incision Management Therapy System)
Description: After cesarean delivery, women in the intervention group will receive PREVENA Incision Management Therapy System.
Study NCT03269968 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Standard dressing
Description: After cesarean delivery, women in the intervention group will receive standard dressing.
Study NCT01096368 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 3-Dimensional Conformal Radiation Therapy
Description: Patients undergo conformal radiotherapy
Study NCT01096368 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-Dimensional Conformal Radiation Therapy
Description: Patients undergo conformal radiotherapy
Study NCT01096368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT01096368 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Given IV
Study NCT01096368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study NCT01096368 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical Observation
Description: Patients undergo observation
Study NCT01096368 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Given IV
Study NCT01096368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT02980887 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: There is no intervention in this observational study
Study NCT04473963 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrographic Flow™ guided ablation
Description: In addition to standard pulmonary vein isolation (PVI) or PVI touch-up, subjects receive targeted radiofrequency source ablation guided by Electrographic Flow™ (EGF) mapping. EGF mapping enables the full spatiotemporal reconstruction of organized atrial electrical wavefront propagation to identify active sources or origins of excitation that may trigger atrial fibrillation (AF).~EGF mapping involves 1 minute recordings of unipolar electrograms from a basket catheter, which are then processed with the EGF software. Several basket catheter positions are acquired in standard positions in both the left and right atria. EGF-identified sources with activity above the threshold (≥ 26.5%) are considered significant and targeted for ablation. The procedure concludes when all EGF-identified sources are eliminated, defined as reducing source activity below the threshold.
Study NCT01096368 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: Given IV
Study NCT01096368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV
Study NCT01096368 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Filgrastim
Description: Given SC or IV
Study NCT01096368 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given SC or IV
Study NCT01096368 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Optional correlative studies
Study NCT01096368 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Optional correlative studies
Study NCT01096368 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mesna
Description: Given IV
Study NCT01096368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: Given IV
Study NCT01096368 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine
Description: Given IV
Study NCT01096368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given IV
Study NCT01445509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Once the MTD of dasatinib with bevacizumab 5 mg/kg IV every two weeks is determined, one final dose level will be accrued with that MTD dose of dasatinib with bevacizumab at 10 mg/kg IV every two weeks in order to determine if we can safely escalate bevacizumab to full dose with dasatinib concurrently.
Study NCT00881582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alfa-2a plus ribavarin
Description: PEG-interferon alfa-2a and ribavirin. Pegylated interferon alfa-2a - standard dose; plus ribavirin - standard dose (determined by creatinine clearance); for 24 to 48 weeks (genotypes 1 \& 4: 48 weeks; genotypes 2 \& 3: 24 weeks)
Study NCT01445509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: We will start dasatinib at 50 mg PO QD which is less than half the recommended Phase 2 dose as well as bevacizumab at 5 mg/kg IV every two weeks, which is half the single agent dose. If this is well-tolerated, study drugs will be escalated per schema to maximize the dose of dasatinib when given concurrently.
Study NCT02231775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Given PO
Study NCT03752580 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: User Instructions of novel nasal mask
Description: User Unstructions interpretation of novel nasal mask for the treatment of obstructive sleep apnea (OSA).
Study NCT01904591 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Selenium
Description: Selenium 50 micrograms daily per oral~1 year of treatment
Study NCT01904591 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin E
Description: Vitamin E 400 international units daily per oral~1 year of treatment
Study NCT01150864 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Airway Conditioning
Description: Each Passive device will be changed daily. When using Active and Passive devices as well as Active-Passive devices the ventilatory circuit will be changed every 7 days.
Study NCT02231775 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02231775 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery
Study NCT02231775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Given PO
Study NCT03862781 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Right Hemicolectomy
Description: Minimally invasive approach (robotic or laparoscopic) with the creation of an anastomosis.